Zydus Cadila gets USFDA nod to market anti-inflammatory drug

Zydus Cadila has received approval from the US health regulator to market anti- inflammatory Diflunisal tablets in America.

"The company has received final approval from the United States Food and Drug Administration (USFDA) to market Diflunisal tablets in the strength of 500 mg", Zydus group firm Cadila Healthcare said in a statement.

The product is a nonsteroidal anti-inflammatory drug and will be produced at the group's formulations manufacturing facility at Baddi, it added.

"The group now has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs)", Cadila Healthcare said.

Cadila Healthcare stock closed at Rs 523.80, down 1.38 per cent, on BSE.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)